Cosmos Health Inc. (COSM)
| Market Cap | 14.72M +19.7% |
| Revenue (ttm) | 69.49M +29.8% |
| Net Income | -21.13M |
| EPS | -0.59 |
| Shares Out | 54.34M |
| PE Ratio | n/a |
| Forward PE | 3.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,288,373 |
| Open | 0.2600 |
| Previous Close | 0.2467 |
| Day's Range | 0.2510 - 0.2760 |
| 52-Week Range | 0.2452 - 1.3200 |
| Beta | 4.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 21, 2026 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), N... [Read more]
Financial Performance
In 2025, Cosmos Health's revenue was $65.27 million, an increase of 19.93% compared to the previous year's $54.43 million. Losses were -$19.14 million, -14.45% less than in 2024.
Financial StatementsNews
Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its...
Cosmos Health explores monetization of non-core assets
Cosmos Health (COSM) announced it is exploring the monetization of non-core assets, having identified approximately $20M in assets that can be converted to liquidity without impacting the company’s op...
Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value
Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 million Proceeds could fund a me...
Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the exten...
Cosmos Health says targeting $200M in revenue by 2029
Cosmos Health (COSM) announced guidance for the 2026-2029 period. “Momentum has carried into 2026 across all core segments, with the company expecting to surpass $90M in revenue in 2026, representing…
Cosmos Health sees FY26 revenue surpassing $90M, one est. $87.3M
09:37 EDT Cosmos Health (COSM) sees FY26 revenue surpassing $90M, one est. $87.3M
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segments Gross profit growing 801% to $71.2M: Margins expanding fro...
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
No dilution to existing shareholders Reduction in total outstanding warrant overhang Simplifies capital structure CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or ...
Cosmos Health reports Q1 revenue $17.93M vs $13.71M last year
Greg Siokas, CEO of Cosmos Health (COSM), stated: “Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted…
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in con...
Cosmos Health pursues research, development financing program with EIB
Cosmos Health (COSM) announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development financing program with the European Investment Bank, EIB...
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program €25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D program Institutio...
Cosmos Health announces withdrawal of registration statement on Form S-1
Cosmos Health (COSM) filed with the U.S. Securities and Exchange Commission a request for withdrawal of the Company’s Registration Statement on Form S-1, originally filed on December 18, 2024 and…
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that ...
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is...
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 report EPS outlook upgraded: Zacks now expects Cosmos Health to c...
Cosmos Health sees over $2.5M incremental annual revenue from Cur18 in U.S.
Cosmos Health (COSM) announced that it is projecting Cur18b to generate over $2.5M in incremental annual revenue in the United States within the next 12 to 18 months, based on…
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced tha...
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinic...
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturin...
Cosmos Health announces planned U.S. market launch of Cur18b
Cosmos Health (COSM) announced the planned Q2 U.S. market launch of Cur18b, a next-generation curcumin supplement. Cur18b “enters the U.S. curcumin category as a science-driven alternative to conventi...
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a compositio...
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the...
Cosmos Health reports FY25 adjusted EPS (12c) vs. (65c) last year
Reports FY25 revenue $65.3M vs. $54.3M last year. Greg Siokas, CEO, stated: “2025 was the year Cosmos Health (COSM) proved its model. Not with promises – with numbers. We delivered…
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments
Scaled contract manufacturing division, securing long-term agreements for over 12 million units Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase order...